Stocktoria
CVRx, Inc. CVRX
CVRx, Inc. (CVRX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $56.7M at a -94.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.04 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.843 |
| Retained earnings / assets | -5.636 |
| EBIT / assets | -0.489 |
| Equity / liabilities | 0.601 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CVRX | CVRx, Inc. | 3/9 | -15.5 | — | +10.4% |
| LNSR | LENSAR, Inc. | 2/9 | -10.17 | — | +9.2% |
| APYX | Apyx Medical Corp | 5/9 | -0.11 | — | +9.9% |
| CARL | CARLSMED, INC. | 5/9 | 4.88 | — | +85.9% |
| SI | SHOULDER INNOVATIONS, INC. | 4/9 | 7.68 | — | +49.6% |
| PDEX | PRO DEX INC | 6/9 | 8.16 | 21.9 | +23.7% |
| TLSI | TriSalus Life Sciences, Inc. | 4/9 | — | — | +53.4% |
About CVRx, Inc.
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
FAQ
Is CVRX financially healthy?
CVRx, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CVRX pay a dividend?
No, CVRx, Inc. does not currently pay a dividend.
How profitable is CVRX?
In FY2025, CVRx, Inc. had a net margin of -94.1% and a return on equity of -135.6%.
What is the analyst price target for CVRX?
The average Wall-Street price target for CVRx, Inc. is $11.17, about 309.0% above the recent price, from 6 analysts.
Is CVRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CVRx, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.